Dr Benoit You MD PhD
is an academic staff physician working within Medical Oncology department of Lyon University Hospital (Centre Hospitalier Lyon-Sud; Lyon; France). He is the head of the phase 1 trial unit oncology group (Centre d’Investigation des Thérapeutiques en Oncologie et Hématologie de Lyon, CITOHL, http://www.pols-phase1.eu/
), certified by French National Cancer Institute (Institut National du Cancer). Moreover he works with pharmacokinetic-pharmacodynamic modeling laboratory (EMR UCBL/HCL 3738) of Lyon 1 University (Faculté de médecine Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1).
Graduated from Université Claude Bernard Lyon 1 (France) in 2008, he is a French medical oncologist. He has focused his research toward 2 areas:
- Mathematical modeling of serum tumor markers. With his research team, he has developed semi-mechanistic models to describe kinetics of serum tumor markers during treatment (PSA, CA-125, hCG, CTCs…). Based on promising results, Dr You has linked strong collaborations with international collaborative groups such as NCIC, US GOG, Charing Cross/Royal Marsden Hospital, GINECO … to validate the role of mathematical modeling in analysis of traditional or modern serum tumor markers.
- Early phase clinical trials and drug development. During a 18 month fellowship in Drug Development Program of Princess Margaret Hospital (Toronto, Canada), one of the phase 1 trial centers granted by the US NCI, Dr Benoit You improved his skills in phase 1 trial designing and leading between 2008 and 2010. Within CITOHL, Lyon phase 1 trial unit, he conducts industrial and academic phase 1 and 2 clinical trials. Dr You and collaborators are developing multi-parameters phase 1 trials, based on novel phase 1 trial designs, meant to determine the study drug doses and dosing schedules able to maximize benefit/toxicity ratio using mathematical modeling and simulations.
Over the past 10 years, Dr You is the first author of many articles, related to pharmacology, drug development, clinical trials & tumor marker modeling, published in international journals (Index H = 22). To lead his research projects, he has received 11 grants and awards, including the Bourse Walter-Zelidja from Académie Française, the Fellowship award from Ontario Institute for Cancer Research, as well as 2 Merit Awards from American Society of Clinical Oncology and International Society for Study of Gestational Trophoblastic Diseases.